M. Pfreundschuh
-
- CAR-T cell therapy research 2
-
- Lymphoma Diagnosis and Treatment 7
-
- Lung Cancer Treatments and Mutations 2
- Renal cell carcinoma treatment 1
-
- Monoclonal and Polyclonal Antibodies Research 4
- Radiopharmaceutical Chemistry and Applications 2
-
- Glycosylation and Glycoproteins Research 1
-
- Cancer Research and Treatments 1
- Co-authors
- Bernd MetznerH. J. IlligerG. JakseJens AtzpodienChristoph RennerH. KirchnerU. RebmannE Lopez Hänninen
- Journals
- Journal of Clinical Oncology (2 papers)Cancer Immunology Immunotherapy (2 papers)British Journal of Haematology (1 paper)
- Partner nations
- GermanyUnited StatesAustralia
In The Last Decade
M. Pfreundschuh
14 papers receiving 211 citations
Peers
Comparison fields: 5 of 43
- Oncology 117
- Pathology and Forensic Medicine 71
- Immunology 70
- Genetics 33
- Pulmonary and Respiratory Medicine 71
Countries citing papers authored by M. Pfreundschuh
This map shows the geographic impact of M. Pfreundschuh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Pfreundschuh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Pfreundschuh more than expected).
Fields of papers citing papers by M. Pfreundschuh
This network shows the impact of papers produced by M. Pfreundschuh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Pfreundschuh. The network helps show where M. Pfreundschuh may publish in the future.
Co-authorship network
The 25 scholars most cited alongside M. Pfreundschuh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 7 | |
| 2 | 2011 | 2 | |
| 3 | 2010 | 24 | |
| 4 | 2010 | 6 | |
| 5 | The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantel cell lymphomas (MCL) - Results of a prospective randomized comparison of the German low grade study group (GLSG). | 2001 | 0 |
| 6 | 2001 | 7 | |
| 7 | 2001 | 4 | |
| 8 | Increased Efficacy Through Moderate Dose Escalation of Chemotherapy: Interim Report From the HD9 Randomized Trial for Advanced Hodgkin’s Disease | 1999 | 1 |
| 9 | 1998 | 23 | |
| 10 | 1997 | 4 | |
| 11 | 1996 | 20 | |
| 12 | 1996 | 1 | |
| 13 | 1995 | 99 | |
| 14 | Increased levels of circulating cytokines in patients with untreated Hodgkin's disease. | 1992 | 23 |
| 15 | 1991 | 4 |
About M. Pfreundschuh
M. Pfreundschuh is a scholar working on Pathology and Forensic Medicine, Nephrology and Oncology, having authored 15 papers that have together received 225 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (7 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Radiopharmaceutical Chemistry and Applications (2 papers), CAR-T cell therapy research (2 papers), Lung Cancer Treatments and Mutations (2 papers), Glycosylation and Glycoproteins Research (1 paper), Cancer Research and Treatments (1 paper) and Renal cell carcinoma treatment (1 paper). The work is most often cited by research in Oncology (117 citations), Pathology and Forensic Medicine (71 citations) and Immunology (70 citations). M. Pfreundschuh has collaborated with scholars based in Germany, United States and Australia. Frequent co-authors include Bernd Metzner, H. J. Illiger, G. Jakse, Jens Atzpodien, Christoph Renner, H. Kirchner, U. Rebmann, E Lopez Hänninen, Frank Hartmann and Wolfram Jung. Their work appears in journals such as Journal of Clinical Oncology, Cancer Immunology Immunotherapy, British Journal of Haematology, Annals of Oncology and Annals of Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.